Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANS011
MIFTS: 47

Anus Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anus Cancer

About this section

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer 12 15
Anal Cancer 12 54 44
Malignant Neoplasm of Anus 74
Malignant Anal Tumor 12
Cancer of the Anus 54
Anus Neoplasms 74
Anal Carcinoma 74

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:14110
ICD9CM 36 154.2 154.3
NCIt 51 C7379
SNOMED-CT 69 93669004 93676009
ICD10 34 C21.0 C21.1
Sources

Summaries for Anus Cancer

About this section
NIH Rare Diseases : 54 Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus. Signs and symptoms of the condition include rectal bleeding; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes. In most cases, the underlying cause of anal cancer is unknown. There appears to be a link between anal cancer and the human papillomavirus (HPV) infection. Other risk factors for anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system. The best treatment options for anal cancer depend on many factors including the stage of the condition, the location of the tumor and if there are associated conditions (i.e. HIV) but may include surgery, chemotherapy, and radiation therapy.

MalaCards based summary : Anus Cancer, also known as anal cancer, is related to anal canal carcinoma and anus disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Anus Cancer is SERPINB3 (Serpin Family B Member 3). The drugs Oxaliplatin and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include testes, lymph node and skin.

Disease Ontology : 12 A large intestine cancer that is located in the anus.

MedlinePlus : 44 The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

Wikipedia : 77 Anal cancer is a cancer (malignant tumor) which arises from the anus, the distal opening of the... more...

Sources

Related Diseases for Anus Cancer

About this section

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 anal canal carcinoma 29.8 CD6 CDKN2A KRT7
2 anus disease 29.7 CDKN2A DCXR SERPINB3 SMUG1
3 hemorrhoid 11.4
4 vulva squamous cell carcinoma 10.4 CDKN2A SERPINB3
5 rectum squamous cell carcinoma 10.4 DCXR SMUG1
6 anal canal squamous cell carcinoma 10.4 CDKN2A SERPINB3
7 rectosigmoid junction neoplasm 10.4 DCXR SMUG1
8 pleural cancer 10.3 CDKN2A SMUG1
9 descending colon cancer 10.3 DCXR SMUG1
10 hypopharynx cancer 10.3 CD6 SMUG1
11 cervix uteri carcinoma in situ 10.3 CDKN2A KLHL40
12 uterus carcinoma in situ 10.3 CDKN2A KLHL40
13 tongue disease 10.3 CD6 CDKN2A
14 laryngeal disease 10.2 CD6 CDKN2A
15 inverted transitional papilloma 10.2 CDKN2A KRT7
16 pharynx cancer 10.2 CD6 CDKN2A SMUG1
17 small cell carcinoma 10.2 CDKN2A KRT7
18 vulval paget's disease 10.2 CDKN2A KRT7
19 adenoid basal cell carcinoma 10.2 CDKN2A KRT7
20 nasopharyngeal disease 10.2 CD6 CDKN2A SMUG1
21 bile duct adenoma 10.2 CDKN2A KRT7
22 endocervical carcinoma 10.2 CDKN2A KRT7
23 malignant spiradenoma 10.2 KRT7 SMUG1
24 bladder carcinoma in situ 10.2 CDKN2A KRT7
25 esophageal disease 10.2 CDKN2A SMUG1
26 gallbladder small cell carcinoma 10.2 KRT7 SMUG1
27 nasal cavity cancer 10.2 CDKN2A KRT7
28 jejunal adenocarcinoma 10.2 KRT7 SMUG1
29 nasal cavity adenocarcinoma 10.2 CDKN2A KRT7
30 vulva adenocarcinoma 10.2 CDKN2A KRT7
31 cecal benign neoplasm 10.2 KRT7 SMUG1
32 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A KRT7
33 eccrine adenocarcinoma 10.2 KRT7 SMUG1
34 human immunodeficiency virus infectious disease 10.2
35 cervix disease 10.1 CDKN2A SMUG1
36 mucinous bronchioloalveolar adenocarcinoma 10.1 CDKN2A KRT7
37 prostate squamous cell carcinoma 10.1 KRT7 SMUG1
38 well-differentiated liposarcoma 10.1 CDKN2A KRT7
39 rectum adenocarcinoma 10.1 DCXR KRT7
40 horner's syndrome 10.1 CD6 KRT7
41 cervical squamous cell carcinoma 10.1 CDKN2A SERPINB3
42 endocervical adenocarcinoma 10.1 CDKN2A KRT7
43 nasal cavity squamous cell carcinoma 10.1 CDKN2A KRT7
44 necrotizing sialometaplasia 10.1 CDKN2A KRT7
45 basaloid squamous cell carcinoma 10.1 CDKN2A KRT7
46 cervical adenosquamous carcinoma 10.1 CDKN2A KRT7
47 adenocarcinoma in situ 10.1 CDKN2A KRT7
48 pericardium cancer 10.1 KRT7 SMUG1
49 tonsil cancer 10.1 CDKN2A KRT7
50 cecum adenocarcinoma 10.1 KRT7 SMUG1

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia

Graphical network of the top 20 diseases related to Anus Cancer:



Diseases related to Anus Cancer
Sources

Symptoms & Phenotypes for Anus Cancer

About this section

UMLS symptoms related to Anus Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, pruritus ani, gastrointestinal gas
Sources

Drugs & Therapeutics for Anus Cancer

About this section

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
2 Immunoglobulins Phase 4,Phase 2,Phase 1
3 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antibodies Phase 4,Phase 2,Phase 1
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Pharmaceutical Solutions Phase 4,Not Applicable
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
15
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
18 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
20 Anesthetics Phase 3,Phase 1,Not Applicable
21 interferons Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
28 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antineoplastic Agents, Hormonal Phase 3
31 Gastrointestinal Agents Phase 3,Phase 2
32 Analgesics Phase 3,Phase 2
33 Adjuvants, Anesthesia Phase 3
34 Anesthetics, General Phase 3
35 Narcotics Phase 3
36 Anesthetics, Intravenous Phase 3
37 Analgesics, Opioid Phase 3
38 Central Nervous System Depressants Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 3,Phase 2
40 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
41 Interferon Inducers Phase 3
42
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
43
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
46
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
47
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
48
Cidofovir Approved Phase 2 113852-37-2 60613
49
Panitumumab Approved, Investigational Phase 2,Phase 1 339177-26-3 50070211
50
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907

Interventional clinical trials:

(show top 50) (show all 199)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
4 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
5 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
6 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
7 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
8 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Completed NCT01164722 Phase 3
9 An Investigational Study of Gardasilâ„¢ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
10 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
11 Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
12 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed NCT01461096 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
15 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
16 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
17 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
18 Immunogenicity From 1 Dose of Bivalent HPV Vaccine in Girls to 3 Doses of Quadrivalent Vaccine in Women: the PRIMAVERA-ESCUDDO Trial Not yet recruiting NCT03728881 Phase 3
19 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
20 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
21 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
22 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
23 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
24 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
25 SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Completed NCT00052897 Phase 1, Phase 2
26 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
27 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
28 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Completed NCT00550589 Phase 2 cidofovir
29 Vectibix for the Treatment of Anal Cancer Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
30 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
31 Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men Completed NCT00428285 Phase 2
32 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
33 Erlotinib in Treating Patients With Advanced Kidney Cancer Completed NCT00045487 Phase 2 OSI-774
34 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
35 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
36 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
37 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed NCT01717391 Phase 2 fluorothymidine F 18
38 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
39 Pembrolizumab in Refractory Metastatic Anal Cancer Recruiting NCT02919969 Phase 2 Pembrolizumab
40 Proton Therapy in Reducing Toxicity in Anal Cancer Recruiting NCT03018418 Phase 2 Chemotherapy
41 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
42 Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Recruiting NCT03381352 Phase 2 Capecitabine;Mitomycin C
43 A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
44 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Recruiting NCT03233711 Phase 2
45 Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
46 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Recruiting NCT03499795 Phase 2
47 LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
48 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
49 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
50 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Recruiting NCT03302858 Phase 2

Search NIH Clinical Center for Anus Cancer

Sources

Genetic Tests for Anus Cancer

About this section
Sources

Anatomical Context for Anus Cancer

About this section

MalaCards organs/tissues related to Anus Cancer:

42
Testes, Lymph Node, Skin, Lung, Liver, Bone, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Anus Cancer:

20
The Anus
Sources

Publications for Anus Cancer

About this section

Articles related to Anus Cancer:

(show top 50) (show all 799)
# Title Authors Year
1
Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. ( 30608547 )
2019
2
HPV-Associated Anal Cancer in the HIV/AIDS Patient. ( 30523625 )
2019
3
Factors associated with anal cancer screening follow-up by high-resolution anoscopy. ( 29934358 )
2019
4
Anal Cancer: Putting Health-Related Quality of Life at the Forefront. ( 30415785 )
2019
5
Association of anal symptoms with anal high grade squamous intraepithelial lesions (HSIL) among men who have sex with men: Baseline data from the study of the prevention of anal cancer (SPANC). ( 30439602 )
2019
6
Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer? ( 30583927 )
2019
7
Dosimetric comparison of helical tomotherapy and VMAT for anal cancer: A single institutional experience. ( 30639142 )
2019
8
Erythema Gyratum Repens Associated with Anal Cancer. ( 30650327 )
2019
9
Sexual Function in Women with Colorectal/Anal Cancer. ( 30655196 )
2019
10
Circulating tumor DNA in advanced anal cancer: a blood biomarker goes viral. ( 30655314 )
2019
11
Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer. ( 30659127 )
2019
12
Comparative accuracy of qualitative and quantitative 18F-FDG PET/CT analysis in detection of lymph node metastasis from anal cancer. ( 30694369 )
2019
13
A Team-Based Approach to Anal Cancer Screening and Prevention. ( 30741771 )
2019
14
Feasibility of screening for anal cancer in HIV-positive people older than 50 years in Canada. ( 30745404 )
2019
15
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. ( 30755500 )
2019
16
Racial and gender disparities in the incidence of anal cancer: analysis of the Nationwide Inpatient Sample (NIS). ( 30788157 )
2019
17
Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. ( 30810343 )
2019
18
Anal Cancer in the Era of Dose Painted Intensity Modulated Radiation Therapy: Implications for Regional Nodal Therapy. ( 30827451 )
2019
19
Knowledge of Anal Cancer, Anal Cancer Screening, and HPV in HIV-Positive and High-Risk HIV-Negative Women. ( 30850945 )
2019
20
New Insights into the Role of Human Papillomavirus in Anal Cancer and Anal Wart Development. ( 30861525 )
2019
21
Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer. ( 30888976 )
2019
22
Risk of Invasive Anal Cancer in HIV-Infected Patients With High-Grade Anal Dysplasia: A Population-Based Cohort Study. ( 30888979 )
2019
23
HPV-circulating tumoural DNA by droplet-based digital polymerase chain reaction, a new molecular tool for early detection of HPV metastatic anal cancer? A case report. ( 30909071 )
2019
24
Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. ( 28665010 )
2018
25
Effect of CD4 Count on Treatment Toxicity and Tumor Recurrence in Human Immunodeficiency Virus-Positive Patients With Anal Cancer. ( 29102276 )
2018
26
Sociodemographic Predictors of Anal Cancer Screening and Follow-up in Human Immunodeficiency Virus-Infected Individuals. ( 28723723 )
2018
27
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. ( 29720197 )
2018
28
Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer. ( 29722659 )
2018
29
Systemic Therapies for Advanced Squamous Cell Anal Cancer. ( 29728940 )
2018
30
Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis. ( 29759568 )
2018
31
Patterns of care for anal cancer in the United States - a comparison between academic and community cancer centers. ( 29769057 )
2018
32
A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients. ( 29771796 )
2018
33
The impact of contour variation on tumour control probability in anal cancer. ( 29776418 )
2018
34
Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences. ( 29804324 )
2018
35
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. ( 29859793 )
2018
36
Anal Cancer Prevention Perspectives Among Foreign-Born Latino HIV-Infected Gay and Bisexual Men. ( 29925247 )
2018
37
Prospective evaluation of acute toxicity and patient reported outcomes in anal cancer and plan optimization. ( 29929860 )
2018
38
Determinants for local tumour control probability after radiotherapy of anal cancer. ( 29934107 )
2018
39
Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation. ( 29953269 )
2018
40
Erratum: E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line. ( 29966543 )
2018
41
Correction: Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. ( 29975772 )
2018
42
GI Cancers-Modulating the Modern Management of Gastrointestinal Malignancies: A Look at Liver Metastases, Rectal Cancer, Esophagogastric Cancer, and Anal Cancer. ( 29976479 )
2018
43
An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. ( 29980478 )
2018
44
Utilization of intensity modulated radiation therapy for anal cancer in the United States. ( 29998012 )
2018
45
Patterns of complications following urinary tract reconstruction after multivisceral surgery in colorectal and anal cancer. ( 30017328 )
2018
46
Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. ( 30026613 )
2018
47
Brachytherapy boost after chemoradiation in anal cancer: a systematic review. ( 30038645 )
2018
48
Building evidence-based treatment recommendations for advanced anal cancer: the time is now. ( 30042062 )
2018
49
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( 30049649 )
2018
50
Host cell DNA methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer. ( 30060049 )
2018
Sources

Variations for Anus Cancer

About this section
Sources

Expression for Anus Cancer

About this section
Search GEO for disease gene expression data for Anus Cancer.
Sources

Pathways for Anus Cancer

About this section
Sources

GO Terms for Anus Cancer

About this section
Sources

Sources for Anus Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....